Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.73 |
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.73 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.52 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050709 | 0.92 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL420150 | 0.92 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL444903 | 0.91 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| Phosphoric Acid SCHEMBL9905234 | 0.91 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL29357308 | 0.84 | HSP90AB1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL419884 | 0.84 | HSP90AB1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL444904 | 0.84 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL419889 | 0.81 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1304910 | 0.80 | HSP90AB1 (0.58) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12486604 | 0.79 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678014-A2 | PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2014-01-01 | — | — | EP | claimed |
| EP-2663305-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH PROTEASOME INHIBITORS | Synta Pharmaceuticals Corp. (US) | 2013-11-20 | — | — | EP | claimed |
| EP-2648708-A2 | COMBINATION FOR BREAST CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2013-10-16 | — | — | EP | claimed |
| WO-2012141796-A2 | PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-10-18 | — | — | WO | claimed |
| WO-2012116247-A1 | HSP90 INHIBITORY COMPOUNDS IN TREATING JAK/STAT SIGNALING-MEDIATED CANCERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-30 | — | — | WO | claimed |
| WO-2012096919-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH PROTEASOME INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | WO | claimed |
| WO-2012078757-A2 | COMBINATION BREAST CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-14 | — | — | WO | claimed |
| EP-2663305-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH PROTEASOME INHIBITORS | Synta Pharmaceuticals Corp. (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2648708-A2 | COMBINATION FOR BREAST CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | Synta Pharmaceuticals Corp. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012116247-A1 | HSP90 INHIBITORY COMPOUNDS IN TREATING JAK/STAT SIGNALING-MEDIATED CANCERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012096919-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH PROTEASOME INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012078757-A2 | COMBINATION BREAST CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-14 | — | — | WO | disclosed |